The coronavirus pandemic caused by novel SARS-COV-2 (Severe acute respiratory syndrome coronavirus 2) began in WUHAN city, CHINA In December 2019 and has spread worldwide.The first case in india was reported on 30th January 2020 in kerala. SARS-COV2 is a single starded RNA enveloped virus, target cells through the viral structural spike (S) protein that binds to the angiotensin-coverting enzyme 2(ACE2) receptor.Therapies including remedisvir,azithromycin,plasma therapy, stem inhalation ,gargles, and 7 pointer healthy lifestyle. Till date 5.51 million people have recovered worldwide and 24.3million have recovered in India. This battle shall end soon with emerging vaccines coming up. Without vaccines also the treatment results are promising against this pandemic. Also seen people with good immunity are not at all getting exposed to the virus on exposure, due to healthy living.
Cite this article:
Ritika Gupta. The Management of Coronavius Pandemic 2019-2020. Asian J. Pharm. Res. 2020; 10(4):327-330. doi: 10.5958/2231-5691.2020.00056.8
Ritika Gupta. The Management of Coronavius Pandemic 2019-2020. Asian J. Pharm. Res. 2020; 10(4):327-330. doi: 10.5958/2231-5691.2020.00056.8 Available on: https://asianjpr.com/AbstractView.aspx?PID=2020-10-4-14
1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. Published online March 4, 2020. doi: 10.1016/j.cell.2020.02.052
2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423. doi:10.1002/jmv. 25681
3. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015; 1282:1-23. doi:10.1007/978-1-4939- 2438-7_1
4. Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate immunity. Front Microbiol. 2014; 5:296. doi:10.3389/fmicb. 2014. 00296
5. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-727. doi:10.1016/S1473-3099(03) 00806-5
6. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293. doi:10. 1002/prp2.293
7. Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015; 135:1171–8.
8. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;25(145):104228.
9. Kawamura K, Ichikado K, Suga M, Yoshioka M. Efficacy of azithromycin for treatment of acute exacerbation of chronic fibros- ing interstitial pneumonia: a prospective, open-label study with historical controls. Respiration. 2014; 87:478–84.
10. Bush A, Cunningham S, de Blic J, Barbato A, Clement A, Epaud R, on behalf of the chILD-EU Collaboration, et al. European pro- tocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015; 70:1078–84.
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical fea- tures of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506.
12. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavi- rus disease 2019. J Clin Investig. 2020; 130:2620–9.
13. McGonaglea D, Sharifa K, O’Regand A, Bridgewooda C. The role of cytokines including interleukin-6 in COVID-19 induced pneu- monia and macrophage activation syndrome-like disease. Autoim- mune Rev. 2020. https://doi.org/10.1016/j.autrev. 2020.102537.
14. Cai M, Bonella F, Dai H, Sarria R, Guzman J, Costabel U. Mac- rolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013; 218:930–7.
15. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012; 68:479–503.
16. Silva JC, Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL, et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo). 2013; 68:766–71.
17. Durcan L, Petri M. Immunomodulators in SLE: clinical evidence and immunologic actions. JAutoimmun. 2016; 74:73–84.